MedTrace Logo

Nephroprotective Effect of Nicorandil in Type 2 Diabetes Mellitus

NCT06430125 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2024-05-28

No results posted yet for this study

Summary

This study aims to evaluate the possible nephroprotective effect of nicorandil in patients with type 2 diabetes mellitus .

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

Nicorandil 10 MG Oral Tablet

Nicorandil 10 MG oral tablet twice daily

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-28
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06430125 on ClinicalTrials.gov